fosun pharma's amoxicillin capsules passes consistency evaluations for generic drugs
amoxicillin capsules is mainly used for the treatment of adult and child infections caused by sensitive bacteria (no β-lactamase producing strains). the drug is the first product of gpsc passing the consistency evaluations and the first product in guangxi passing the consistency evaluations after the launch of the consistency evaluation policy. therefore, it has positive significance to the consistency evaluations for generic drugs in guangxi. up until november 2019, gpsc’s cumulative r&d investment in the drug’s consistency performance was some rmb6.55 million.
fosun pharma stated, that amoxicillin capsules has passed the consistency evaluations for generic drugs can effectively increase its competitiveness in the market and be beneficial to market sales, while accumulating experience for the company to conduct research on generic drug consistency evaluation for other products in subsequent stage. in response to calls for centralized procurement of drugs covered by national health insurance, fosun pharma has focused on r&d innovation as its major development driving factor, so as to continuously bolster the pharmaceutical r&d system for generic-proprietary integration and actively promote the nmpa’s consistency evaluations for generic drugs.